A multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and effect of taspoglutide compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Next Previous
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and effect of taspoglutide compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Taspoglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms T-EMERGE-1
  • Sponsors Roche

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jul 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top